CanSinoBIO’s inhalation COVID-19 shot in mid-stage trial, says CEO

FILE PHOTO: A logo of China’s vaccine specialist CanSino Biologics Inc is pictured in Tianjin, China August 17, 2020. REUTERS/Thomas Peter

(Reuters) – An inhalation version of CanSino Biologics’ (6185.HK), COVID-19 vaccine is being tested in a Phase II clinical trial, Chief Executive Yu Xuefeng said late on Wednesday.

Yu made the comment at a panel of the Global Health Forum of the Boao Forum for Asia.

Our Standards: The Thomson Reuters Trust Principles.


Reuters source: